Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: bob beck who wrote (1157)	6/23/1998 9:45:00 AM
From: HeyRainier	Read Replies (1) \| Respond to of 4140

That introduces an element of competition that will serve to reduce the net market share for future hyperopia-based market players. Rainier

To: bob beck who wrote (1157)	6/23/1998 9:47:00 AM
From: HeyRainier	Read Replies (2) \| Respond to of 4140

By the way, doesn't VISX have to go through all three phases to get their new technology process approved? Can they just leap-frog the whole process just because they have a pre-approved, less-related process? Regards, Rainier

To: bob beck who wrote (1157)	6/23/1998 11:16:00 AM
From: Joe	Read Replies (1) \| Respond to of 4140

If the CEO of Laser Vision Centers is correct, I think the FDA will go out of their way to have both products (LTK and PRK or LASIK for hyperopia) addressed at the same panel meeting. The FDA has a history of not giving a company that has gone through a relatively short clinical trial period like Visx with hyperopia over a company that has gone through a very long period of clinical trials as is the case with LTK and Sunrise. Beyond the FDA's history regarding their sensitivity to competitive issues between companies, will be their desire to have a less invasive procedure ready and able to compete with a move invasive one like PRK or LASIK.